151 related articles for article (PubMed ID: 12814461)
21. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring.
Jerling M; Alván G
Eur J Clin Pharmacol; 1994; 46(1):67-70. PubMed ID: 8005189
[TBL] [Abstract][Full Text] [Related]
22. Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.
Shaw GL; Weiffenbach B; Falk RT; Frame JN; Issaq HJ; Moir DT; Caporaso N
Lung Cancer; 1997 May; 17(1):61-8. PubMed ID: 9194027
[TBL] [Abstract][Full Text] [Related]
23. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
24. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.
Ryu S; Park S; Lee JH; Kim YR; Na HS; Lim HS; Choi HY; Hwang IY; Lee JG; Park ZW; Oh WY; Kim JM; Choi SE
Clin Transl Sci; 2017 Mar; 10(2):93-101. PubMed ID: 28296334
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic interaction between nortriptyline and terbinafine.
Van Der Kuy PH; Van Den Heuvel HA; Kempen RW; Vanmolkot LM
Ann Pharmacother; 2002 Nov; 36(11):1712-4. PubMed ID: 12398564
[TBL] [Abstract][Full Text] [Related]
26. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
27. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
28. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
Lee SY; Ki CS; Hong KS; Kim JW
J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
[TBL] [Abstract][Full Text] [Related]
29. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.
Morita S; Shimoda K; Someya T; Yoshimura Y; Kamijima K; Kato N
J Clin Psychopharmacol; 2000 Apr; 20(2):141-9. PubMed ID: 10770451
[TBL] [Abstract][Full Text] [Related]
30. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
[TBL] [Abstract][Full Text] [Related]
32. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
[TBL] [Abstract][Full Text] [Related]
33. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.
Aklillu E; Herrlin K; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 2002 Jul; 12(5):375-83. PubMed ID: 12142727
[TBL] [Abstract][Full Text] [Related]
34. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
36. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
[TBL] [Abstract][Full Text] [Related]
37. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
38. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan.
Chen CH; Hung CC; Wei FC; Koong FJ
Psychiatr Genet; 2001 Sep; 11(3):153-5. PubMed ID: 11702057
[TBL] [Abstract][Full Text] [Related]
39. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
